argenx SE (EBR:ARGX)
Belgium
· Delayed Price · Currency is EUR | Market Cap | 30.69B |
| Revenue (ttm) | 2.45B |
| Net Income (ttm) | 984.51M |
| Shares Out | 61.06M |
| EPS (ttm) | 14.75 |
| PE Ratio | 34.09 |
| Forward PE | 40.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,984 |
| Average Volume | 64,262 |
| Open | 500.80 |
| Previous Close | 505.80 |
| Day's Range | 500.00 - 509.80 |
| 52-Week Range | 348.20 - 658.00 |
| Beta | 0.04 |
| RSI | 42.88 |
| Earnings Date | Jul 31, 2025 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
News
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease
ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod RHO data show efgartigimod achieved sustained reduction in auto...
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease
ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod RHO data show efgartigimod achieved sustained reduction in auto...
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
June 3, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno...
argenx Announces Results of Annual General Meeting of Shareholders
May 28, 2025 – 10:01 PM C ET
Hot Picks in biotech: argenx, Scholar Rock & Kiniksa
David Nierengarten, senior analyst at Wedbush, shares his hot picks in the biotech sector: argenx SE, Scholar Rock and Kiniksa Pharmaceuticals.
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
These large-cap stocks were the worst performers in the last week. Are they in your portfolio? argenx SE (NASDAQ: ARGX) shares tumbled 15.40% after the company reported first-quarter results . Vertex...
Argenx Q1 Earnings: Less Than Perfect Report Gets Punished
Argenx targets Vision 2030 with 50,000 patients and 10 labeled indications by 2025
argenx SE (ARGX) Q1 2025 Earnings Call Transcript
Argenx plunges after Q1 revenue miss
Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble
Argenx stock tumbled Thursday after its drug, Vyvgart, beat sales expectations. But the beat wasn't strong enough for investors.
Earnings Scheduled For May 8, 2025
Companies Reporting Before The Bell • Sempra (NYSE: SRE) is likely to report quarterly earnings at $1.32 per share on revenue of $3.92 billion. • Warner Music Gr (NASDAQ: WMG) is projected to report...
Argenx reports mixed Q1 results; reaffirms FY25 outlook
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opin...
A Look Into argenx Inc's Price Over Earnings
In the current session, the stock is trading at $622.93, after a 1.27% increase. Over the past month, argenx Inc. (NASDAQ: ARGX) stock increased by 10.42% , and in the past year, by 62.84% . With per...
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million ; Adjusted EBIT...
argenx to Present at BofA Securities 2025 Health Care Conference
May 6, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
May 1, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...
Argenx Stock Extends Rally In A Base As Earnings Loom
Argenx stock is rising Wednesday as the major indexes sell off. The autoimmune disease treatment stock is climbing in an early-stage base.
P/E Ratio Insights for argenx
In the current session, the stock is trading at $632.41, after a 1.84% spike. Over the past month, argenx Inc. (NASDAQ: ARGX) stock increased by 11.52% , and in the past year, by 64.97% . With perfor...
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection ...
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | ARGX Stock News
argenx SE (ARGX) Receives Positive CHMP Opinion for VYVGART® in CIDP Treatment | ARGX stock news
argenx SE (ARGX) Receives Positive CHMP Opinion for VYVGART® in CIDP Treatment | ARGX stock news
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ...
What's Driving the Market Sentiment Around argenx?
argenx's (NYSE: ARGX) short percent of float has fallen 3.8% since its last report. The company recently reported that it has 2.15 million shares sold short , which is 3.54% of all regular shares tha...
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options. Latest Ratings for ... Full story available on Ben...